News

An unnamed weight loss drug maker's stock fell 25% after new safety data revealed concerning side effects for its experimental drug, despite the drug meeting its primary efficacy endpoints. Analysts are questioning the commercial viability of the drug given the side effect profile. No specific company or ticker is named in the article.

Boehringer Ingelheim and Zealand Pharma's obesity drug has shown promising results in reducing visceral and liver fat, according to Reuters. The data suggests potential efficacy beyond weight loss, targeting metabolically harmful fat deposits. No further trial phase or regulatory filing details are provided in the headline.

Replimune plans to resubmit a drug that has been rejected twice by the FDA, following recent organizational changes at the agency. The company had previously criticized the FDA for what it described as inconsistent guidance around clinical trials and approvals. The resubmission signals renewed confidence that the regulatory environment may be more favorable under the restructured FDA.